APRE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways...

Stats
Today's Volume	7 192.00
Average Volume	34 140.00
Market Cap	29.05M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.780 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.350
ATR14	$0.0750 (1.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Hamill John P.	Buy	3 365	Common Stock
2024-03-28	Hamill John P.	Buy	13 460	Stock Options (Right to Buy)
2024-03-28	Gilad Oren	Buy	6 725	Common Stock
2024-03-28	Gilad Oren	Buy	26 900	Stock Options (Right to Buy)
2024-03-13	Hamill John P.	Buy	1 010	Common Stock

INSIDER POWER
89.82
Last 96 transactions
Buy: 13 026 874 \| Sell: 1 205 176

Aprea Therapeutics Inc Correlation

10 Most Positive Correlations
VRNA	0.895
TTOO	0.886
EOLS	0.869
STRO	0.863
JD	0.862
REVB	0.861
ASPU	0.86
AVIR	0.858
VREX	0.858
DCGO	0.856

10 Most Negative Correlations
GOODM	-0.886
SHSP	-0.873
PAE	-0.87
MGTA	-0.853
SGLB	-0.852
KIN	-0.85
EBSB	-0.85
CSII	-0.848
OP	-0.845
SCR	-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aprea Therapeutics Inc Financials

Annual	2023
Revenue:	$583 231
Gross Profit:	$576 178 (98.79 %)
EPS:	$-3.95

Q4	2023
Revenue:	$14 075.00
Gross Profit:	$9 089.00 (64.58 %)
EPS:	$-0.920

Q3	2023
Revenue:	$319 468
Gross Profit:	$319 468 (100.00 %)
EPS:	$-0.860

Q2	2023
Revenue:	$249 688
Gross Profit:	$249 688 (100.00 %)
EPS:	$-0.870

Financial Reports:

No articles found.

Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.